[go: up one dir, main page]

AR022857A1 - Acido dihidroxilado de ciclo abierto y sales de los inhibidores de hmg-co-a reductasa - Google Patents

Acido dihidroxilado de ciclo abierto y sales de los inhibidores de hmg-co-a reductasa

Info

Publication number
AR022857A1
AR022857A1 ARP000101007A ARP000101007A AR022857A1 AR 022857 A1 AR022857 A1 AR 022857A1 AR P000101007 A ARP000101007 A AR P000101007A AR P000101007 A ARP000101007 A AR P000101007A AR 022857 A1 AR022857 A1 AR 022857A1
Authority
AR
Argentina
Prior art keywords
hmg
acid
dihydroxyled
reductasa
inhibitors
Prior art date
Application number
ARP000101007A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR022857A1 publication Critical patent/AR022857A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion provee métodos y composiciones farmacéuticas para inhibir la HMG-CoA reductasa, así como también tratar y/o reducir el riesgo deenfermedades y condiciones afectadas por la inhibicion de HMG-CoA reductasa, que comprende administrar oralmente una cantidad terapéuticamente efectiva de unaforma cristalina hidratada de sal de calcio de simvastatina de ácido dihidroxilado de ciclo abierto a un paciente que necesita dicho tratamiento. También seproveen los métodos para preparar lasal de calcio de simvastatina de ácido dihidroxilado de ciclo abierto.
ARP000101007A 1999-03-08 2000-03-07 Acido dihidroxilado de ciclo abierto y sales de los inhibidores de hmg-co-a reductasa AR022857A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12324799P 1999-03-08 1999-03-08
US26474599A 1999-03-09 1999-03-09
PCT/US2000/002627 WO2000053566A1 (en) 1999-03-08 2000-02-02 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt

Publications (1)

Publication Number Publication Date
AR022857A1 true AR022857A1 (es) 2002-09-04

Family

ID=26821372

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101007A AR022857A1 (es) 1999-03-08 2000-03-07 Acido dihidroxilado de ciclo abierto y sales de los inhibidores de hmg-co-a reductasa

Country Status (16)

Country Link
EP (2) EP1163203A1 (es)
JP (2) JP2002539108A (es)
AR (1) AR022857A1 (es)
AT (1) ATE240934T1 (es)
AU (1) AU764048B2 (es)
CA (1) CA2365869A1 (es)
CO (1) CO5150184A1 (es)
DE (1) DE60002769T9 (es)
DK (1) DK1036783T3 (es)
ES (1) ES2198253T3 (es)
HN (1) HN2000000031A (es)
PE (1) PE20001469A1 (es)
PT (1) PT1036783E (es)
SI (1) SI1036783T1 (es)
SV (1) SV2002000035A (es)
WO (1) WO2000053566A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6558659B2 (en) 2000-04-10 2003-05-06 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
WO2002020457A1 (en) * 2000-09-06 2002-03-14 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
EP1322306A2 (en) * 2000-09-19 2003-07-02 NovImmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
CZ2004943A3 (cs) 2002-03-18 2005-02-16 Biocon Limited Amorfní HMG-CoA inhibitory obsahující reduktázu s požadovanou velikostí částic
US20030195167A1 (en) * 2002-04-15 2003-10-16 Kowa Co., Ltd. PTX3-gene expression inhibitor
DK1515717T3 (da) * 2002-06-13 2009-02-09 Novartis Ag Calciumsalte af indolafledte statiner
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
KR20050098313A (ko) 2003-02-11 2005-10-11 플러스 케미칼스 비.브이. 제어된 범위의 심바스타틴 이량체 함량을 갖는심바스타틴의 제조 방법
EP1790635A3 (en) 2003-06-18 2007-06-13 Teva Pharmaceutical Industries, Inc. Processes for preparing amorphous fluvastatin sodium
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
US7368581B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
JPWO2006115130A1 (ja) * 2005-04-19 2008-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ビス［（２ｓ）−３−［３−［（２ｓ）−３−（４−クロロ−２−シアノフェノキシ）−２−フルオロプロポキシ］フェニル］−２−イソプロポキシプロピオン酸］カルシウム及びその中間体
US7816405B2 (en) 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
KR20130100297A (ko) * 2010-08-27 2013-09-10 어드밴스드 테크놀러지 머티리얼즈, 인코포레이티드 건조 동안의 높은 종횡비 구조물의 붕괴 방지 방법
WO2014036548A1 (en) * 2012-08-31 2014-03-06 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Macromolecular prodrugs for hard tissue and methods of use thereof
GB201704687D0 (en) 2017-03-24 2017-05-10 Wockhardt Uk Ltd Pharmaceutical composition of simvastatin or salt thereof
CN113686991A (zh) * 2021-08-31 2021-11-23 南京西默思博检测技术有限公司 测定人血浆中辛伐他汀、β-羟酸辛伐他汀的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)

Also Published As

Publication number Publication date
EP1163203A1 (en) 2001-12-19
EP1036783A1 (en) 2000-09-20
SI1036783T1 (en) 2003-08-31
ES2198253T3 (es) 2004-02-01
EP1036783B1 (en) 2003-05-21
DE60002769D1 (de) 2003-06-26
WO2000053566A1 (en) 2000-09-14
AU2637000A (en) 2000-09-28
AU764048B2 (en) 2003-08-07
DK1036783T3 (da) 2003-06-23
ATE240934T1 (de) 2003-06-15
PT1036783E (pt) 2003-08-29
JP2002539108A (ja) 2002-11-19
CO5150184A1 (es) 2002-04-29
SV2002000035A (es) 2002-01-15
DE60002769T9 (de) 2004-11-04
PE20001469A1 (es) 2000-12-18
HN2000000031A (es) 2001-09-25
DE60002769T2 (de) 2004-03-18
JP2000281626A (ja) 2000-10-10
CA2365869A1 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
AR022857A1 (es) Acido dihidroxilado de ciclo abierto y sales de los inhibidores de hmg-co-a reductasa
AR022856A1 (es) Acido abierto dihidroxi y sales de inhibidores de hmg-co-a reductasa
ECSP23054131A (es) Cocristal de un inhibidor de cdk
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
EA200900821A1 (ru) Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
BR0317183A (pt) Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
CY1108301T1 (el) Συνθεση περιλαμβανουσα αναστολεα αποακετυλασης ιστονης εμφανιζουσα διφασικη απελευθερωση
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы
GT199900148A (es) Desnaturalizantes para las sales aminas simpaticomimeticas.
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MX2012002761A (es) Bipiridinas utiles para el tratamiento de enfermedades proliferativas.
SG178975A1 (en) Indenone derivative and pharmaceutical composition comprising same
MX2012002758A (es) Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
BR0316877A (pt) Derivados de aril-quinazolina/aril-2-amino-fenil metanona que promovem a liberação de hormÈnio da paratireóide
TW200728260A (en) Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof
CO2021014210A2 (es) Compuestos de pirrol
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
UA117046C2 (uk) [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ ПРОТОЗОЙНИХ ПРОТЕАСОМ ДЛЯ ЛІКУВАННЯ ПАРАЗИТАРНИХ ЗАХВОРЮВАНЬ, ТАКИХ ЯК ЛЕЙШМАНІОЗ
MX2011011687A (es) Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer.
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan